Yes, through the 503A patient-specific compounding pathway - though the landscape has changed materially since 2023
The BBB issued a pattern-of-complaints alert in April 2025 for delivery delays and unresponsive support
Learn the essential storage conditions for lyophilised and reconstituted peptides, and avoid common mistakes that compromise research quality
Powder Forms of Retatrutide: Regulatory Status and Risks Retatrutide powder sold outside clinical trials is unlicensed, has no validated stability or purity data, and carries serious risks including contamination, incorrect dosing, and infection
GLP-ONE Support Multivitamin Nutrient Renewal is designed to address the unique nutritional gaps commonly seen in patients taking GLP-1 RA medications.*
in: PubMed | Google Scholar 1 Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland